Published in EMBO Mol Med on November 01, 2010
50 years of hurdles and hope in anxiolytic drug discovery. Nat Rev Drug Discov (2013) 1.28
Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning? Nat Rev Drug Discov (2012) 1.22
Toward an integration of cognitive and genetic models of risk for depression. Cogn Emot (2012) 0.99
NPY and stress 30 years later: the peripheral view. Cell Mol Neurobiol (2012) 0.97
NPY receptors as potential targets for anti-obesity drug development. Br J Pharmacol (2011) 0.96
Neuropeptide Y and posttraumatic stress disorder. Mol Psychiatry (2012) 0.93
Neuropeptide Y acts in the paraventricular nucleus to suppress sympathetic nerve activity and its baroreflex regulation. J Physiol (2014) 0.91
GPCR-I-TASSER: A Hybrid Approach to G Protein-Coupled Receptor Structure Modeling and the Application to the Human Genome. Structure (2015) 0.90
Can neuropeptides treat obesity? A review of neuropeptides and their potential role in the treatment of obesity. Br J Pharmacol (2013) 0.89
How to fix a broken clock. Trends Pharmacol Sci (2013) 0.88
Targeting the Neuropeptide Y System in Stress-related Psychiatric Disorders. Neurobiol Stress (2015) 0.87
Integration of optogenetics with complementary methodologies in systems neuroscience. Nat Rev Neurosci (2017) 0.86
Fluorescence correlation spectroscopy, combined with bimolecular fluorescence complementation, reveals the effects of β-arrestin complexes and endocytic targeting on the membrane mobility of neuropeptide Y receptors. Biochim Biophys Acta (2012) 0.84
Computational prediction of alanine scanning and ligand binding energetics in G-protein coupled receptors. PLoS Comput Biol (2014) 0.82
Schizophrenia and Depression Co-Morbidity: What We have Learned from Animal Models. Front Psychiatry (2015) 0.79
Administration of the Y2 receptor agonist PYY3-36 in mice induces multiple behavioral changes relevant to schizophrenia. Neuropsychopharmacology (2013) 0.79
PTPRT regulates high-fat diet-induced obesity and insulin resistance. PLoS One (2014) 0.78
Altered expression of neuropeptide Y receptors caused by focal cortical dysplasia in human intractable epilepsy. Oncotarget (2016) 0.78
Quantitative sensory testing and pain-evoked cytokine reactivity: comparison of patients with sickle cell disease to healthy matched controls. Pain (2016) 0.78
Identification of a small-molecule ligand that activates the neuropeptide receptor GPR171 and increases food intake. Sci Signal (2016) 0.78
Design and Synthesis of Peptide YY Analogues with C-terminal Backbone Amide-to-Ester Modifications. ACS Med Chem Lett (2013) 0.76
The neuropeptide Y Y1 receptor knockdown modulates activator protein 1-involved feeding behavior in amphetamine-treated rats. Mol Brain (2013) 0.75
Corexit-EC9527A Disrupts Retinol Signaling and Neuronal Differentiation in P19 Embryonal Pluripotent Cells. PLoS One (2016) 0.75
NPY1 Receptor Agonist Modulates Development of Depressive-Like Behavior and Gene Expression in Hypothalamus in SPS Rodent PTSD Model. Front Neurosci (2017) 0.75
Emerging drugs for the treatment of anxiety. Expert Opin Emerg Drugs (2015) 0.75
Bone Injury and Repair Trigger Central and Peripheral NPY Neuronal Pathways. PLoS One (2016) 0.75
C-terminal amidation of PACAP-38 and PACAP-27 is dispensable for biological activity at the PAC1 receptor. Peptides (2016) 0.75
Ligands of the neuropeptide Y Y2 receptor. Bioorg Med Chem Lett (2013) 0.75
Recent advances in the understanding of how neuropeptide Y and α-melanocyte stimulating hormone function in adipose physiology. Adipocyte (2016) 0.75
Appetite-Controlling Endocrine Systems in Teleosts. Front Endocrinol (Lausanne) (2017) 0.75
Genome-wide association study of vitamin D levels in children: replication in the Western Australian Pregnancy Cohort (Raine) study. Genes Immun (2014) 0.75
Neuropeptide Y Negatively Influences Monocyte Recruitment to the Central Nervous System during Retrovirus Infection. J Virol (2015) 0.75
Gut-Brain Endocrine Axes in Weight Regulation and Obesity Pharmacotherapy. J Clin Med (2014) 0.75
Arcuate neuropeptide Y inhibits sympathetic nerve activity via multiple neuropathways. J Clin Invest (2017) 0.75
RNA-seq analysis of amygdala tissue reveals characteristic expression profiles in schizophrenia. Transl Psychiatry (2017) 0.75
MicroRNA's impact on neurotransmitter and neuropeptide systems: small but mighty mediators of anxiety. Pflugers Arch (2016) 0.75
Gut hormone PYY(3-36) physiologically inhibits food intake. Nature (2002) 8.30
Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell (2000) 7.87
Obese, a new mutation in the house mouse. J Hered (1950) 5.33
Neuropeptide Y--a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature (1982) 4.06
Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature (1996) 3.99
The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature (1995) 3.67
Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med (2007) 3.36
The NPY system in stress, anxiety and depression. Neuropeptides (2004) 2.51
Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides. Nature (1980) 2.31
Evidence for different pre-and post-junctional receptors for neuropeptide Y and related peptides. Regul Pept (1986) 2.05
Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab (2006) 2.02
Hypothalamic Y2 receptors regulate bone formation. J Clin Invest (2002) 2.01
A receptor subtype involved in neuropeptide-Y-induced food intake. Nature (1996) 1.96
Patterns of gene expression are altered in the frontal and motor cortices of human alcoholics. J Neurochem (2002) 1.91
Neuropeptide Y functions as a neuroproliferative factor. Nature (2001) 1.78
Role of the Y5 neuropeptide Y receptor in feeding and obesity. Nat Med (1998) 1.70
Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res (1998) 1.62
Isolation and characterization of a new pancreatic polypeptide hormone. J Biol Chem (1975) 1.55
Cloned human neuropeptide Y receptor couples to two different second messenger systems. Proc Natl Acad Sci U S A (1992) 1.53
Hippocampal neurogenesis as a target for the treatment of mental illness: a critical evaluation. Neuropharmacology (2010) 1.50
Meal-induced peptide tyrosine tyrosine inhibition of pancreatic secretion in the rat. FASEB J (1989) 1.47
Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science (1993) 1.43
Chemically mediated cross-excitation in rat dorsal root ganglia. J Neurosci (1996) 1.41
BIIE0246: a selective and high affinity neuropeptide Y Y(2) receptor antagonist. Eur J Pharmacol (1999) 1.38
Y4 receptor knockout rescues fertility in ob/ob mice. Genes Dev (2002) 1.38
Neurobiology of substance P and the NK1 receptor. J Clin Psychiatry (2002) 1.35
Neuropeptide Y potentiates noradrenaline-evoked vasoconstriction: mode of action. J Pharmacol Exp Ther (1985) 1.34
Neuropeptide Y induces migration, proliferation, and tube formation of endothelial cells bimodally via Y1, Y2, and Y5 receptors. FASEB J (2006) 1.33
Peptide YY abnormalities in gastrointestinal diseases. Gastroenterology (1986) 1.32
Neuropeptide tyrosine (NPY)--a major cardiac neuropeptide. Lancet (1983) 1.31
Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor. Nat Med (1999) 1.31
Mechanisms of neuropeptide Y, peptide YY, and pancreatic polypeptide inhibition of identified green fluorescent protein-expressing GABA neurons in the hypothalamic neuroendocrine arcuate nucleus. J Neurosci (2005) 1.30
Deletion of neuropeptide Y (NPY) 2 receptor in mice results in blockage of NPY-induced angiogenesis and delayed wound healing. Proc Natl Acad Sci U S A (2003) 1.28
Obesity and mild hyperinsulinemia found in neuropeptide Y-Y1 receptor-deficient mice. Proc Natl Acad Sci U S A (1998) 1.26
Suppression of ethanol self-administration by the neuropeptide Y (NPY) Y2 receptor antagonist BIIE0246: evidence for sensitization in rats with a history of dependence. Neurosci Lett (2004) 1.24
Chronic stress, combined with a high-fat/high-sugar diet, shifts sympathetic signaling toward neuropeptide Y and leads to obesity and the metabolic syndrome. Ann N Y Acad Sci (2008) 1.24
Cloning and functional expression of a human neuropeptide Y/peptide YY receptor of the Y1 type. J Biol Chem (1992) 1.23
Neuropeptide Y gene polymorphisms confer risk of early-onset atherosclerosis. PLoS Genet (2009) 1.20
Cloning and functional expression of a human Y4 subtype receptor for pancreatic polypeptide, neuropeptide Y, and peptide YY. J Biol Chem (1995) 1.18
Neuropeptide Y in the dentate gyrus. Prog Brain Res (2007) 1.17
A functional neuropeptide Y Leu7Pro polymorphism associated with alcohol dependence in a large population sample from the United States. Arch Gen Psychiatry (2002) 1.16
Neuropeptide Y receptor subtypes, Y1 and Y2. Ann N Y Acad Sci (1990) 1.15
Greater bone formation of Y2 knockout mice is associated with increased osteoprogenitor numbers and altered Y1 receptor expression. J Biol Chem (2007) 1.14
Novel role of Y1 receptors in the coordinated regulation of bone and energy homeostasis. J Biol Chem (2007) 1.14
Reduced antinociception and plasma extravasation in mice lacking a neuropeptide Y receptor. Nature (2001) 1.12
Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors. Cancer Res (2005) 1.11
Neuropeptide tyrosine and pain. Trends Pharmacol Sci (2007) 1.11
Neuropeptide Y (NPY) Y2 receptors mediate behaviour in two animal models of anxiety: evidence from Y2 receptor knockout mice. Behav Brain Res (2003) 1.09
Neuropeptide Y, Y1, Y2 and Y4 receptors mediate Y agonist responses in isolated human colon mucosa. Br J Pharmacol (2002) 1.09
Orexin activation precedes increased NPY expression, hyperphagia, and metabolic changes in response to sleep deprivation. Am J Physiol Endocrinol Metab (2010) 1.06
Cloning and functional expression of a cDNA encoding a human type 2 neuropeptide Y receptor. J Biol Chem (1995) 1.06
Neuropeptide Y receptor genes are associated with alcohol dependence, alcohol withdrawal phenotypes, and cocaine dependence. Alcohol Clin Exp Res (2008) 1.04
Fat-induced ileal brake in the dog depends on peptide YY. Gastroenterology (1996) 1.03
Common neuropeptide Y2 receptor gene variant is protective against obesity among Swedish men. Int J Obes (Lond) (2006) 1.03
Blockade of central neuropeptide Y (NPY) Y2 receptors reduces ethanol self-administration in rats. Neurosci Lett (2002) 1.02
The neuropeptides CCK and NPY and the changing view of cell-to-cell communication in the taste bud. Physiol Behav (2009) 1.02
Hypothalamic regulation of cortical bone mass: opposing activity of Y2 receptor and leptin pathways. J Bone Miner Res (2006) 1.02
The effects of social isolation on neuropeptide Y levels, exploratory and anxiety-related behaviors in rats. Pharmacol Biochem Behav (2006) 1.00
Neuropeptide Y receptors; antisecretory control of intestinal epithelial function. Auton Neurosci (2006) 1.00
Inactivation of a novel neuropeptide Y/peptide YY receptor gene in primate species. J Biol Chem (1996) 0.99
Expression cloning and pharmacological characterization of a human hippocampal neuropeptide Y/peptide YY Y2 receptor subtype. J Biol Chem (1995) 0.99
NPY regulation of bone remodelling. Neuropeptides (2009) 0.99
Potent and selective tools to investigate neuropeptide Y receptors in the central and peripheral nervous systems: BIB03304 (Y1) and CGP71683A (Y5). Can J Physiol Pharmacol (2000) 0.99
Neuropeptide Y (NPY) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y5 receptors. Proc Natl Acad Sci U S A (2000) 0.98
Selective and brain penetrant neuropeptide y y2 receptor antagonists discovered by whole-cell high-throughput screening. Mol Pharmacol (2009) 0.98
Correlation of gut hormones with irritable bowel syndrome. Digestion (2008) 0.97
The neuropeptide Y Y1 antagonist, 1229U91, a potent agonist for the human pancreatic polypeptide-preferring (NPY Y4) receptor. Peptides (1998) 0.97
Assessment of ethanol consumption and water drinking by NPY Y(2) receptor knockout mice. Peptides (2004) 0.96
Neuropeptide Y stimulates proliferation of human vascular smooth muscle cells: cooperation with noradrenaline and ATP. Regul Pept (1994) 0.95
Gut hormones: a weight off your mind. J Neuroendocrinol (2008) 0.95
Cloning and expression of a novel neuropeptide Y receptor. J Biol Chem (1996) 0.94
Neuropeptide Y2 receptor protein is present in peptidergic and nonpeptidergic primary sensory neurons of the mouse. J Comp Neurol (2005) 0.94
Plasma neuropeptide Y on admission to a coronary care unit: raised levels in patients with left heart failure. Cardiovasc Res (1990) 0.93
Neuropeptide Y overexpression using recombinant adeno-associated viral vectors. Neurotherapeutics (2009) 0.93
Regulation of neuropeptide Y release by neuropeptide Y receptor ligands and calcium channel antagonists in hypothalamic slices. J Neurochem (1999) 0.93
Attenuation of acute experimental colitis by preventing NPY Y1 receptor signaling. Am J Physiol Gastrointest Liver Physiol (2004) 0.92
NPY family of hormones: clinical relevance and potential use in gastrointestinal disease. Curr Top Med Chem (2007) 0.92
Neuropeptide Y promotes sleep and inhibits ACTH and cortisol release in young men. Neuropharmacology (2000) 0.92
Exogenous neuropeptide Y promotes in vivo hippocampal neurogenesis. Hippocampus (2011) 0.92
Neuropeptide Y in phaeochromocytomas and ganglioneuroblastomas. Lancet (1983) 0.91
Anticonvulsant effects and behavioural outcomes of rAAV serotype 1 vector-mediated neuropeptide Y overexpression in rat hippocampus. Gene Ther (2010) 0.91
Modulation of neuropeptide Y receptors for the treatment of obesity. Expert Opin Ther Pat (2009) 0.91
In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y(2) receptor. Psychopharmacology (Berl) (2009) 0.90
Molecular characterization of a second mouse pancreatic polypeptide receptor and its inactivated human homologue. J Biol Chem (1996) 0.90
On the intrinsic regulation of neuropeptide Y release in the mammalian suprachiasmatic nucleus circadian clock. Eur J Neurosci (2010) 0.90
Opioid-like actions of neuropeptide Y in rat substantia gelatinosa: Y1 suppression of inhibition and Y2 suppression of excitation. J Neurophysiol (2004) 0.90
Relevance of neuropeptide Y (NPY) in psychiatry. Curr Top Med Chem (2007) 0.90
PYY3-36 as an anti-obesity drug target. Obes Rev (2005) 0.90
NPY and cardiac diseases. Curr Top Med Chem (2007) 0.88
Role of neuropeptide Y Y(2) receptors in modulation of cardiac parasympathetic neurotransmission. Regul Pept (2002) 0.88
Agonist and antagonist activities on human NPFF(2) receptors of the NPY ligands GR231118 and BIBP3226. Br J Pharmacol (2001) 0.87
Differential expression of NPY and its receptors in alcohol-preferring AA and alcohol-avoiding ANA rats. Alcohol Clin Exp Res (2001) 0.87
Reduced neuropeptide Y concentrations in suicide brain. J Neurochem (1992) 0.87
Calcitonin gene-related peptide regulates expression of neurokinin1 receptors by rat spinal neurons. J Neurosci (2003) 0.86
The therapeutic potential of gut hormone peptide YY3-36 in the treatment of obesity. Expert Opin Investig Drugs (2005) 0.85
The neuropeptide tyrosine Y1R is expressed in interneurons and projection neurons in the dorsal horn and area X of the rat spinal cord. Neuroscience (2006) 0.85
Neuropeptide chronomics in clinically healthy young adults: circaoctohoran and circadian patterns. Peptides (2004) 0.85
Intracerebroventricular neuropeptide Y protects against stress-induced gastric erosion in the rat. Eur J Pharmacol (1987) 0.84
Peripheral hyperalgesia in experimental neuropathy: exacerbation by neuropeptide Y. Brain Res (1995) 0.82
Evidence for Y1 and Y2 subtypes of neuropeptide Y receptors linked to opposing postjunctional effects observed in rat cardiac myocytes. Eur J Pharmacol (1997) 0.82
Genome-wide analysis of mammalian promoter architecture and evolution. Nat Genet (2006) 17.19
The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line. Nat Genet (2009) 6.02
Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase. Nat Med (2008) 5.62
Myogenic gene expression signature establishes that brown and white adipocytes originate from distinct cell lineages. Proc Natl Acad Sci U S A (2007) 4.69
Regulatory roles of natural antisense transcripts. Nat Rev Mol Cell Biol (2009) 4.48
Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci U S A (2002) 4.20
Complex Loci in human and mouse genomes. PLoS Genet (2006) 3.74
The reality of pervasive transcription. PLoS Biol (2011) 3.41
Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation. Nat Biotechnol (2012) 3.07
RNAdb--a comprehensive mammalian noncoding RNA database. Nucleic Acids Res (2005) 2.84
Using molecular classification to predict gains in maximal aerobic capacity following endurance exercise training in humans. J Appl Physiol (1985) (2010) 2.74
Striatal microRNA controls cocaine intake through CREB signalling. Nature (2010) 2.56
A systematic analysis of the silencing effects of an active siRNA at all single-nucleotide mismatched target sites. Nucleic Acids Res (2005) 2.27
Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res (2005) 2.20
Evidence for natural antisense transcript-mediated inhibition of microRNA function. Genome Biol (2010) 2.08
MicroRNA-219 modulates NMDA receptor-mediated neurobehavioral dysfunction. Proc Natl Acad Sci U S A (2009) 2.00
Considerations when using the significance analysis of microarrays (SAM) algorithm. BMC Bioinformatics (2005) 1.89
Human muscle gene expression responses to endurance training provide a novel perspective on Duchenne muscular dystrophy. FASEB J (2005) 1.85
A small molecule enhances RNA interference and promotes microRNA processing. Nat Biotechnol (2008) 1.80
Amygdala-dependent fear is regulated by Oprl1 in mice and humans with PTSD. Sci Transl Med (2013) 1.74
Integration of microRNA changes in vivo identifies novel molecular features of muscle insulin resistance in type 2 diabetes. Genome Med (2010) 1.64
Improved and automated prediction of effective siRNA. Biochem Biophys Res Commun (2004) 1.58
A novel RNA transcript with antiapoptotic function is silenced in fragile X syndrome. PLoS One (2008) 1.57
MicroRNA-132 dysregulation in schizophrenia has implications for both neurodevelopment and adult brain function. Proc Natl Acad Sci U S A (2012) 1.49
Pseudo-messenger RNA: phantoms of the transcriptome. PLoS Genet (2006) 1.46
Regulation of chromatin structure by long noncoding RNAs: focus on natural antisense transcripts. Trends Genet (2012) 1.46
Single nucleotide polymorphisms in the proximal promoter region of the adiponectin (APM1) gene are associated with type 2 diabetes in Swedish caucasians. Diabetes (2004) 1.41
MicroRNA dysregulation in psychiatric disease. Brain Res (2010) 1.34
Apoptosis resistance downstream of eIF4E: posttranscriptional activation of an anti-apoptotic transcript carrying a consensus hairpin structure. Nucleic Acids Res (2006) 1.27
Noncoding RNAs: couplers of analog and digital information in nervous system function? Trends Neurosci (2007) 1.27
Intronic RNAs constitute the major fraction of the non-coding RNA in mammalian cells. BMC Genomics (2012) 1.26
RNA interference is not involved in natural antisense mediated regulation of gene expression in mammals. Genome Biol (2006) 1.21
Altered regulation of the PINK1 locus: a link between type 2 diabetes and neurodegeneration? FASEB J (2007) 1.19
Expression profiling following local muscle inactivity in humans provides new perspective on diabetes-related genes. Genomics (2005) 1.18
microRNAs in CNS disorders. Neuromolecular Med (2009) 1.17
Analysis of siRNA specificity on targets with double-nucleotide mismatches. Nucleic Acids Res (2008) 1.14
Validating siRNA using a reporter made from synthetic DNA oligonucleotides. Biochem Biophys Res Commun (2004) 1.14
Small GTP-binding protein Rac is an essential mediator of vascular endothelial growth factor-induced endothelial fenestrations and vascular permeability. Circulation (2003) 1.10
NotI subtraction and NotI-specific microarrays to detect copy number and methylation changes in whole genomes. Proc Natl Acad Sci U S A (2002) 1.10
The human PINK1 locus is regulated in vivo by a non-coding natural antisense RNA during modulation of mitochondrial function. BMC Genomics (2007) 1.10
Personalized medicine in psychiatry: problems and promises. BMC Med (2013) 1.09
Activity-induced and developmental downregulation of the Nogo receptor. Cell Tissue Res (2003) 1.07
Kinetics of senescence-associated changes of gene expression in an epithelial, temperature-sensitive SV40 large T antigen model. Cancer Res (2004) 1.07
Identification of functional SNPs in the 5-prime flanking sequences of human genes. BMC Genomics (2005) 1.07
Effective small interfering RNAs and phosphorothioate antisense DNAs have different preferences for target sites in the luciferase mRNAs. Biochem Biophys Res Commun (2003) 1.06
A new approach to genome mapping and sequencing: slalom libraries. Nucleic Acids Res (2002) 1.05
Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism. J Psychiatr Res (2004) 1.04
Involvement of long noncoding RNAs in diseases affecting the central nervous system. RNA Biol (2012) 1.04
The expression signature of in vitro senescence resembles mouse but not human aging. Genome Biol (2005) 1.03
Platelets activated during myocardial infarction release functional miRNA, which can be taken up by endothelial cells and regulate ICAM1 expression. Blood (2013) 1.03
Selective and brain penetrant neuropeptide y y2 receptor antagonists discovered by whole-cell high-throughput screening. Mol Pharmacol (2009) 0.98
Non-coding RNA transcripts: sensors of neuronal stress, modulators of synaptic plasticity, and agents of change in the onset of Alzheimer's disease. Neurosci Lett (2009) 0.96
hUNC93B1: a novel human gene representing a new gene family and encoding an unc-93-like protein. Gene (2002) 0.96
Epigenetic mechanisms of gene regulation during mammalian spermatogenesis. Epigenetics (2008) 0.95
RNA Interference with chemically modified siRNA. Curr Top Med Chem (2006) 0.93
Human neuropeptide Y signal peptide gain-of-function polymorphism is associated with increased body mass index: possible mode of function. Regul Pept (2005) 0.93
No induction of anti-viral responses in human cell lines HeLa and MCF-7 when transfecting with siRNA or siLNA. Biochem Biophys Res Commun (2006) 0.93
Locked nucleic acid containing antisense oligonucleotides enhance inhibition of HIV-1 genome dimerization and inhibit virus replication. FEBS Lett (2004) 0.92
GeneLynx mouse: integrated portal to the mouse genome. Genome Res (2003) 0.92
NotI flanking sequences: a tool for gene discovery and verification of the human genome. Nucleic Acids Res (2002) 0.92
Association between the nociceptin receptor gene (OPRL1) single nucleotide polymorphisms and alcohol dependence. Addict Biol (2008) 0.91
A novel single nucleotide polymorphism of the neuropeptide Y (NPY) gene associated with alcohol dependence. Alcohol Clin Exp Res (2005) 0.91
NPY Leu7Pro and alcohol dependence in Finnish and Swedish populations. Alcohol Clin Exp Res (2003) 0.90
Functional comparison of single- and double-stranded siRNAs in mammalian cells. Biochem Biophys Res Commun (2004) 0.90
mRNA accessible site tagging (MAST): a novel high throughput method for selecting effective antisense oligonucleotides. Nucleic Acids Res (2003) 0.90
Knockdown of BACE1-AS Nonprotein-Coding Transcript Modulates Beta-Amyloid-Related Hippocampal Neurogenesis. Int J Alzheimers Dis (2011) 0.90
The Emerging Role of Non-Coding RNAs in Drug Addiction. Front Genet (2012) 0.89
The BET-Bromodomain Inhibitor JQ1 Reduces Inflammation and Tau Phosphorylation at Ser396 in the Brain of the 3xTg Model of Alzheimer's Disease. Curr Alzheimer Res (2016) 0.89
A universal plasmid library encoding all permutations of small interfering RNA. Proc Natl Acad Sci U S A (2005) 0.89
Complex HTR2C linkage disequilibrium and promoter associations with body mass index and serum leptin. Hum Genet (2005) 0.89
Genetics of neurological disorders. Expert Rev Mol Diagn (2004) 0.88
Gene characterization index: assessing the depth of gene annotation. PLoS One (2008) 0.86
RNAi screen indicates widespread biological function for human natural antisense transcripts. PLoS One (2010) 0.86
Role of Sirtuin 1 in metabolic regulation. Drug Discov Today (2010) 0.85
Epigenetic pathways and glioblastoma treatment. Epigenetics (2013) 0.85
Characterization of RNA interference in rat PC12 cells: requirement of GERp95. Biochem Biophys Res Commun (2004) 0.85
Behavioural analysis of melanin-concentrating hormone in rats: evidence for orexigenic and anxiolytic properties. Regul Pept (2003) 0.84
Adult neurogenesis: a potential tool for early diagnosis in Alzheimer's disease? J Alzheimers Dis (2010) 0.83
Focusing on RISC assembly in mammalian cells. Biochem Biophys Res Commun (2008) 0.83
Navigating genomic maps of cancer cells. Nat Biotechnol (2010) 0.82
Nonsynonymous SNPs: validation characteristics, derived allele frequency patterns, and suggestive evidence for natural selection. Hum Mutat (2006) 0.82
Transcriptional repression of ER through hMAPK dependent histone deacetylation by class I HDACs. Breast Cancer Res Treat (2014) 0.80
Functional interactions between delta- and mu-opioid receptors in rat thermoregulation. Eur J Pharmacol (2003) 0.79
Anti-cataleptic effects of clozapine, but not olanzapine and quetiapine, on SCH 23390- or raclopride-induced catalepsy in rats. Eur Neuropsychopharmacol (2003) 0.79
Quantitative codon optimisation of DNA libraries encoding sub-random peptides: design and characterisation of a novel library encoding transmembrane domain peptides. Nucleic Acids Res (2002) 0.78
Synthesis and SAR of selective small molecule neuropeptide Y Y2 receptor antagonists. Bioorg Med Chem Lett (2012) 0.77
Analysis of 5-hydroxytryptamine 2c receptor gene promoter variants as alcohol-dependence risk factors. Alcohol Alcohol (2004) 0.76
Vector-based siRNA delivery strategies for high-throughput screening of novel target genes. J RNAi Gene Silencing (2005) 0.76
Oligonucleotides for upregulating gene expression. Pharm Pat Anal (2013) 0.76
Extracellular Uridine Triphosphate and Adenosine Triphosphate Attenuate Endothelial Inflammation through miR-22-Mediated ICAM-1 Inhibition. J Vasc Res (2015) 0.76
RNAi joins the "Singles Club". Mol Ther (2012) 0.75
Exploring the foundation of genomics: a northern blot reference set for the comparative analysis of transcript profiling technologies. Comp Funct Genomics (2004) 0.75
RNA mechanisms in CNS systems and disorders. Brain Res (2010) 0.75
How the strengths of Lisp-family languages facilitate building complex and flexible bioinformatics applications. Brief Bioinform (2017) 0.75
Antisense-induced Fas mRNA degradation produces site-specific stable 3'-mRNA fragment by exonuclease cleavage at the complementary sequence. Oligonucleotides (2004) 0.75
How the strengths of Lisp-family languages facilitate building complex and flexible bioinformatics applications. Brief Bioinform (2016) 0.75